Evaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI.

Çakmak T, Yaşar E, Çakmak E, Tekin S, Karakuş Y, Türkoğlu C, Yüksel F

Arquivos brasileiros de cardiologia9 Jan 2023Cited by 4 (Europe PMC)

PMID36629605PMCIDPMC9833276DOI10.36660/abc.20220358PepBankPUB-36629605

Summary

BackgroundThe protective effects of mitochondrial open reading frame of the 12S rRNA-c (MOTS-C) on cardiovascular diseases have been shown in numerous studies. However, there is little documentation of the relationship between MOTS-C and coronary blood flow in ST-segment elevation myocardial infarction (STEMI).ObjectiveWe aimed to investigate the role of MOTS-C, which is known to have cytoprotective properties in the pathogenesis of the no-reflow phenomenon, by comparing the coronary flow rate and MOTS-C levels in patients with STEMI submitted to primary PCI.Methods52 patients with STEMI and 42 patients without stenosis >50% in the coronary arteries were included in the study. The STEMI group was divided into two groups according to post-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade:(i) No-reflow: grade 0, 1, and 2 and (ii) grade 3(angiographic success). A p value of <0.05 was considered significant.ResultsMOTS-C levels were significantly lower in the STEMI group compared to the control group (91.9 ± 8.9 pg/mL vs. 171.8±12.5 pg/mL, p<0.001). In addition, the Receiver Operating Characteristics (ROC) curve analysis indicated that serum MOTS-C levels had a diagnostic value in predicting no-reflow (Area Under the ROC curve [AUC]:0.95, 95% CI:0.856-0.993, p<0.001). A MOTS-C ≥84.15 pg/mL measured at admission was shown to have 95.3% sensitivity and 88.9% specificity in predicting no-reflow.ConclusionMOTS-C is a strong and independent predictor of no-reflow and in-hospital MACE in patients with STEMI. It was also noted that low MOTS-C levels may be an important prognostic marker of and may have a role in the pathogenesis of STEMI.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with STEMI, serum levels of the body's own MOTS‑C were lower than in control patients without coronary stenosis.
In plain wordsIn people with a heart attack (STEMI), the body's own MOTS‑C levels were lower than in people without blocked arteries.
Peptide
MOTS-c
Outcome
DecreaseSerum MOTS-C level in STEMI versus controls
Study
n = 94
Comparator
Patients without coronary stenosis >50%
Outcome group
Mitochondrial function · Cardiovascular
Measurements
MOTS-C level
91.9 pg/mL
STEMI group
MOTS-C level
171.8 pg/mL
control group
Source sentences
Summary
MOTS-C levels were significantly lower in the STEMI group compared to the control group (91.9 ± 8.9 pg/mL vs. 171.8±12.5 pg/mL, p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
52 patients with STEMI and 42 patients without stenosis >50% in the coronary arteries were included in the study.
Summary · context
The STEMI group was divided into two groups according to post-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade:(i) No-reflow: grade 0, 1, and 2 and (ii) grade 3(angiographic success).
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3662960501
02HumanEndogenous levelObservational studyOther
In patients with STEMI undergoing primary PCI, serum MOTS‑C level had diagnostic value for predicting no-reflow (AUC 0.95).
In plain wordsIn people with a heart attack who had PCI, the body's own MOTS‑C level helped predict poor blood flow after the procedure.
Peptide
MOTS-c
Outcome
Not applicableDiagnostic value of serum MOTS-C for no-reflow (ROC AUC)
Study
n = 52
Outcome group
Cardiovascular events · Cardiovascular
Measurements
AUC
0.95
no-reflow prediction
Source sentences
Summary
In addition, the Receiver Operating Characteristics (ROC) curve analysis indicated that serum MOTS-C levels had a diagnostic value in predicting no-reflow (Area Under the ROC curve [AUC]:0.95, 95% CI:0.856-0.993, p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
52 patients with STEMI and 42 patients without stenosis >50% in the coronary arteries were included in the study.
Summary · context
The STEMI group was divided into two groups according to post-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade:(i) No-reflow: grade 0, 1, and 2 and (ii) grade 3(angiographic success).
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3662960502
03HumanEndogenous levelObservational studyOther
In patients with STEMI, an admission MOTS‑C level of 84.15 pg/mL or higher predicted no-reflow with 95.3% sensitivity and 88.9% specificity.
In plain wordsIn people with a heart attack, the body's own MOTS‑C level at admission predicted poor blood flow after PCI with high sensitivity and specificity.
Peptide
MOTS-c
Outcome
Not applicableSensitivity and specificity of admission MOTS-C for no-reflow
Study
n = 52
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Sensitivity
95.3%
MOTS-C >=84.15 pg/mL
Specificity
88.9%
MOTS-C >=84.15 pg/mL
Source sentences
Summary
A MOTS-C ≥84.15 pg/mL measured at admission was shown to have 95.3% sensitivity and 88.9% specificity in predicting no-reflow.
2 context sentences(design, population, supporting numbers)
Summary · context
52 patients with STEMI and 42 patients without stenosis >50% in the coronary arteries were included in the study.
Summary · context
The STEMI group was divided into two groups according to post-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade:(i) No-reflow: grade 0, 1, and 2 and (ii) grade 3(angiographic success).
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3662960503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.